Needham & Company Maintains a 'Buy' on Aastrom Biosciences (ASTM); 12-Month Phase 2b RESTORE-CLI Data Further Demonstrate Consistent Safety and Efficacy

Needham & Company maintains a 'Buy' on Aastrom Biosciences (NASDAQ: ASTM), PT $6.

Needham analyst says, "Last night, Aastrom reported 12-month results from the RCT Phase 2b RESTORE-CLI trial, evaluating the safety and efficacy of its
expanded, bone marrow-derived cellular therapy, ixmyelocel-T, in patients with critical limb ischemia (CLI). The final analysis of 86 enrolled patients showed a statistically significant improvement in time to treatment failure, the primary endpoint for the trial, as well as a benign safety profile. The detailed data including amputation free survival (primary endpoint for the upcoming pivotal trial) will likely be presented at a 4Q11 medical meeting...We believe that a series of upcoming company events may serve to drive investor interest in regenerative medicine as a whole and ASTM stock in particular."

For more ratings news on Aastrom Biosciences click here and for the rating history of Aastrom Biosciences click here.

Shares of Aastrom Biosciences closed at $3.04 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Wolverine World Wide (WWW) PT Raised to $24 at Needham
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy